Bayer raises sales targets for top-selling drugs after Monsanto deal

Facebook
ВКонтакте
share_fav

FRANKFURT (Reuters) - German drugmaker Bayer said its two best-selling drugs had a higher annual peak sales potential than previously targeted, after the agreed $66 billion takeover of Monsanto stirred criticism it might neglect its pharmaceuticals business.

посмотреть на Reuters: Business